Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity

Lupus. 1993 Feb;2(1):47-50. doi: 10.1177/096120339300200108.

Abstract

Calprotectin (L1) is a granulocyte and monocyte cytosolic protein released during activation of these cells. The plasma level of L1 has been shown to be a good marker of disease activity in rheumatoid arthritis. In this cross-sectional study of 100 patients with systemic lupus erythematosus (SLE), the serum level of L1 was found to be higher in patients than in matched controls (3661 micrograms/l versus 1051 micrograms/l; P < 0.001). The serum level of L1 was the only laboratory parameter with significant association to the disease activity index SLEDAI (r = 0.28; P < 0.01). Furthermore, the serum level of L1 was significantly higher in SLE patients with anti-DNA antibodies compared to patients without anti-DNA antibodies (4501 micrograms/l versus 3279 micrograms/l; P = 0.01). SLE patients with arthritis had higher serum levels of L1 than patients without arthritis (7652 micrograms/l versus 2811 micrograms/l; P < 0.01), indicating that the serum level of L1 also reflects arthritis activity in SLE.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Antinuclear / blood
  • Arthritis, Rheumatoid / blood
  • Biomarkers
  • C-Reactive Protein / metabolism
  • Cell Adhesion Molecules, Neuronal / blood*
  • Female
  • Humans
  • Leukocyte L1 Antigen Complex
  • Lupus Erythematosus, Systemic / blood*
  • Lupus Erythematosus, Systemic / immunology
  • Male
  • Middle Aged

Substances

  • Antibodies, Antinuclear
  • Biomarkers
  • Cell Adhesion Molecules, Neuronal
  • Leukocyte L1 Antigen Complex
  • C-Reactive Protein